ESRRA and breast cancer: Taken together, our study offers a new therapeutic avenue for BC treatment by simultaneously targeting the methionine cycle and DNA methylation via the combined actions of ERRα and DNMT inhibitors, while potentially reducing the toxic side-effects associated to high doses of demethylating agents.